This multilevel meta-analysis examines whether emotional intelligence (EI) can be enhanced through training and identifies training effects’ determinants. We identified 24 studies containing 28 samples aiming at increasing individual-level EI among healthy adults. The results revealed a significant moderate standardized mean change between pre- and post-measurement for the main effect of EI training, and a stable pre- to follow-up effect. Additionally, the type of EI model, dimensions of the four branch model, length, and type of publication turned out to be significant moderators. The results suggest that EI trainings should be considered effective interventions.

Both researchers and practitioners agree that having highly engaged employees results in individuals and organizations reaping various positive consequences related to performance and absenteeism. However, available research syntheses date from the early years of this line of research, thus cover only a small fraction (under 10%) of the available studies. The present meta-analysis updates the results of work engagement and its three facets (vigour, dedication, and absorption) on task performance and includes a substantial number of studies on absenteeism with separate analyses of longitudinal studies. A total of 179 unique correlations representing an overall sample size of N = 139,182 was examined, confirming and enhancing a positive association between work engagement and task performance (ρ = .483) and a negative association between work engagement and absenteeism (ρ = −.171). The three facets of engagement had similar effects on performance, but only vigour and dedication correlated significantly negatively with absenteeism. Work engagement is linked positively to future task performance and negatively to future absenteeism. The influence of several methodical moderators is examined. Finally, we discuss how these findings can inform research and practice in order to contribute to a more effective and healthy work environment for employees.

Objective Disease-modifying treatments (DMTs) are the gold standard for slowing disability progression in multiple sclerosis (MS), but their effects on cognitive impairment, a key symptom of the disease, are mostly unknown. We conducted a systematic review and meta-analysis to evaluate the differential effects of DMTs on cognitive test performance in relapsing-remitting MS (RRMS). Methods PubMed, Scopus, and Cochrane Library were searched for studies reporting longitudinal cognitive performance data related to all major DMTs. The standardized mean difference (Hedges g) between baseline and follow-up cognitive assessment was used as the main effect size measure. Results Forty-four studies, including 55 distinct MS patient samples, were found eligible for the systematic review. Twenty-five studies were related to platform therapies (mainly β-interferon [n = 17] and glatiramer acetate [n = 4]), whereas 22 studies were related to escalation therapies (mainly natalizumab [n = 14] and fingolimod [n = 6]). Reported data were mostly confined to the cognitive domain processing speed. A meta-analysis including 41 studies and 7,131 patients revealed a small to moderate positive effect on cognitive test performance of DMTs in general (g = 0.27, 95% confidence interval [CI] = [0.21–0.33]), but no statistically significant differences between platform (g = 0.27, 95% CI = [0.18–0.35]) and escalation therapies (g = 0.28, 95% CI = [0.19–0.37]) or between any single DMT and β-interferon. Conclusions DMTs are effective in improving cognitive test performance in RRMS, but a treatment escalation mainly to amend cognition is not supported by the current evidence. Given the multitude of DMTs and their widespread use, the available data regarding differential treatment effects on cognitive impairment are remarkably scant. Clinical drug trials that use more extensive cognitive outcome measures are urgently needed.